Evidence map›Paper›PMID 33743103›Full record

ArticleBreast cancer research and treatment2021

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.

Khava I E Ibragimova, Sandra M E Geurts, Sander Croes, Frans Erdkamp, Joan B Heijns, Jolien Tol, Birgit E P J Vriens, Kirsten N A Aaldering, Marcus W Dercksen, Manon J A E Pepels and 6 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03577197 (Southeast Netherlands Advanced Breast Cancer Registry), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03577197 recruitingnot on this map

Southeast Netherlands Advanced Breast Cancer Registry

Typeobservational_patient_registrySponsorAcademisch Ziekenhuis MaastrichtRan2007 to 2027Enrolled7,000ConditionsAdvanced Breast Cancer, Metastatic Breast Cancer
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 2 countries.

Khava I E IbragimovaDepartment of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.
Sandra M E GeurtsDepartment of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.
Sander CroesDepartment of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.
Frans ErdkampDepartment of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, The Netherlands.
Joan B HeijnsDepartment of Medical Oncology, Amphia, Breda, The Netherlands.
Jolien TolDepartment of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands.
Birgit E P J VriensDepartment of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands.
Kirsten N A AalderingDepartment of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
Marcus W DercksenDepartment of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands.
Manon J A E PepelsDepartment of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands.
Natascha A J B PetersDepartment of Internal Medicine, Sint Jans Gasthuis, Weert, The Netherlands.
Linda van de WinkelDepartment of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands.
Dominique J P TilliDepartment of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.
Ingeborg J H VriensDepartment of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.
Maaike de BoerDepartment of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.
Vivianne C G Tjan-HeijnenDepartment of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.ORCID http://orcid.org/0000-0002-3935-7440
University Medical Center · USRadboud University Nijmegen · NLAmphia Ziekenhuis · NLElkerliek Ziekenhuis · NLJeroen Bosch Ziekenhuis · NLLaurentius Ziekenhuis · NLMaastricht University Medical Centre · NLSt. Anna Ziekenhuis · NLSt.Jans Gasthuis Weert · NLZuyderland Medisch Centrum · NL

Funding

Zorginstituut Nederland 80-82500-98-8003
6 · The paper itself

Abstract

purposeImmediate and proper implementation of a new and more potent therapy is important to ensure that the patient achieves the best possible outcome. This study aimed to examine whether the real-world overall survival (OS) has improved in patients with human epidermal growth factor receptor 2-positive (HER2 +) advanced breast cancer (ABC) since the market release of pertuzumab and T-DM1. Furthermore, we aimed to assess the implementation and survival rates per hormone receptor (HR) subtype. PATIENTS AND

methodsWe included 493 systemically treated patients consecutively diagnosed with HER2 + ABC in 2008-2017 from the SOutheast Netherlands Advanced BREast cancer (SONABRE) Registry. Median OS was obtained using the Kaplan-Meier method and differences between periods (2008-2012 versus 2013-2017) were tested using multivariable Cox proportional hazards regression modeling. The 3-year implementation rates were estimated for any HER2-targeted therapy, pertuzumab, and T-DM1 by using the competing risk method and calculated from the date of diagnosis of ABC to start of HER2-targeted therapy of interest.

resultsThe median OS in 2008-2012 versus 2013-2017 was 28.3 versus 39.7 months in all patients (adjusted hazard ratio (adjHR) 0.85, 95%CI 0.66-1.08), 29.9 versus 36.3 months in patients with HR + /HER2 + disease (adjHR 0.97, 95%CI 0.72-1.32), and 22.7 versus 40.9 months in patients with HR-/HER2 + disease (adjHR 0.59, 95%CI 0.38-0.92). Any HER2-targeted therapy was used in 79% of patients in 2008-2012 and in 84% in 2013-2017. The use of pertuzumab and T-DM1 in 2013-2017 was 48% and 29%, respectively. For patients diagnosed with HR + /HER2 + and HR-/HER2 + disease, implementation rates in 2013-2017 were , respectively, 77% and 99% for any HER2-targeted therapy, 38% and 69% for pertuzumab, and 24% and 40% for T-DM1.

conclusionThe survival of patients with HER2 + ABC improved since the introduction of pertuzumab and T-DM1. There is room for improvement in implementation of these HER2-targeted therapies, especially in patients with HR + /HER2 + disease.

Indexed as

Breast NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesFemaleHumansNetherlandsRegistriesTrastuzumabAntibodies, Monoclonal, HumanizedErb-b2 Receptor Tyrosine KinasespertuzumabTrastuzumabBreast neoplasmsHER2-positive diseaseMetastatic breast cancerPertuzumabSurvivalT-DM1

Identifiers

PMID33743103
PMCPMC8260428
OpenAlexW3138028988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.